The addition of Zytiga (abiraterone) to Truqap (capivasertib) significantly prolonged radiographic progression-free survival (rPFS) in patients with PTEN-deficient metastatic hormone-sensitive ...
Capivasertib+abiraterone was associated with more symptomatic AEs but did not impact HRQoL in patients with PTEN-deficient ...
PTEN, a tumor suppressor gene mutated in about 20% of prostate cancers, relies on another gene, ARID4B, to function. PTEN, a tumor suppressor gene mutated in approximately 20% of primary prostate ...
A phase I study of PHY906 as a modulator of irinotecan (CPT-11) in patients with advanced solid tumors. Background: Cellular senescence, an irreversible cell growth arrest, is an intrinsic tumor ...
PTEN is one of the most commonly mutated tumor suppressor genes. It is an antagonist for many cellular growth, proliferation and survival processes. When mutated or deleted, it causes cancers of the ...
Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with FOLFOX4 with or without cetuximab: Lessons from the OPUS trial. Background: Activation of the ...
A collaboration between Saïd M. Sebti, Ph.D., chair of Moffitt Cancer Center's Drug Discovery Department, and Michele Pagano, M.D., chair of the Department of Biochemistry and Molecular Pharmacology ...
A common dietary supplement may help overcome mutations in the Pten gene. Should patients take it? By Gina Kolata When Kelley Oliver Douglass got breast cancer, a genetic counselor posed an odd ...
PTEN, a tumor suppressor gene mutated in approximately 20% of primary prostate cancers, and in as many as 50% of androgen deprivation-resistant prostate cancers, relies on another gene, ARID4B, to ...
PTEN is one of the most commonly mutated tumor suppressor genes. It is an antagonist for many cellular growth, proliferation and survival processes. When mutated or deleted, it causes cancers of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results